FIELD: pharmacology.
SUBSTANCE: invention proposes employment of saredutant and pharmaceutically acceptable salts according to application title.
EFFECT: increased choice of drugs for treatment of depressive disorders.
2 ex
Title | Year | Author | Number |
---|---|---|---|
APPLYING ANTAGONIST OF CENTRAL CANNABINOID RECEPTOR FOR PREPARING DRUGS DESIGNATED FOR RELIEF IN SMOKING CEASING | 2001 |
|
RU2257207C2 |
ORGANIC COMPOUNDS | 2015 |
|
RU2785871C2 |
ANTAGONISTS OF NEUROKININIC RECEPTOR NK-1 FOR ANESTHESIA RECOVERY | 2005 |
|
RU2337685C2 |
PHARMACEUTICAL COMPOSITIONS INCLUDING VALSARTAN AND INHIBITORS OF NEUTRAL ENDOPEPTITAS (NEP) | 2003 |
|
RU2334513C2 |
DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
ORGANIC COMPOUNDS | 2015 |
|
RU2728787C2 |
ANTI-VOMIT NK-1 ANTAGONIST METABOLITES | 2006 |
|
RU2404969C2 |
NOVEL PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2241462C2 |
NEW METHODS | 2014 |
|
RU2682658C1 |
METHOD OF TREATING MAJOR DEPRESSION IN HUMAN | 2007 |
|
RU2445973C2 |
Authors
Dates
2004-10-27—Published
2000-04-25—Filed